Tonya  Austin net worth and biography

Tonya Austin Biography and Net Worth

Insider of AtriCure
Tonya Austin joined AtriCure in May, 2013. She is responsible for all aspects of the company’s global human resources functions including organizational development, employee relations, recruitment, benefits & compensation, performance management, and talent development.   Prior to this, she held several HR leadership roles including an HR Business Partner at Endo Pharmaceuticals, Vice President of Human Resources at Vital Images Inc., and various recruitment/human resource roles at Parametric Technology Corporation (PTC) and PricewatershouseCoopers (PwC).  She graduated from the College of St. Benedict’s in St. Joseph, MN and holds a Senior Professional in Human Resources (SPHR) certification.

What is Tonya Austin's net worth?

The estimated net worth of Tonya Austin is at least $373,565.20 as of May 13th, 2022. Ms. Austin owns 17,621 shares of AtriCure stock worth more than $373,565 as of June 19th. This net worth approximation does not reflect any other assets that Ms. Austin may own. Learn More about Tonya Austin's net worth.

How do I contact Tonya Austin?

The corporate mailing address for Ms. Austin and other AtriCure executives is 7555 INNOVATION WAY, MASON OH, 45040. AtriCure can also be reached via phone at (513) 755-4100 and via email at [email protected]. Learn More on Tonya Austin's contact information.

Has Tonya Austin been buying or selling shares of AtriCure?

Tonya Austin has not been actively trading shares of AtriCure during the last quarter. Most recently, Tonya Austin sold 3,203 shares of the business's stock in a transaction on Friday, May 13th. The shares were sold at an average price of $42.69, for a transaction totalling $136,736.07. Following the completion of the sale, the insider now directly owns 17,621 shares of the company's stock, valued at $752,240.49. Learn More on Tonya Austin's trading history.

Who are AtriCure's active insiders?

AtriCure's insider roster includes Tonya Austin (Insider), Mark Collar (Director), Vinayak Doraiswamy (Insider), Scott Drake (Director), Regina Groves (Director), David Grumhaus, Jr. (Portfolio Manager), Justin Noznesky (Insider), Salvatore Privitera (Insider), Douglas Seith (COO), Sven Wehrwein (Director), and Angela Wirick (CFO). Learn More on AtriCure's active insiders.

Are insiders buying or selling shares of AtriCure?

During the last year, AtriCure insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $111,250.00. During the last year, insiders at the medical device company sold shares 7 times. They sold a total of 19,281 shares worth more than $742,976.93. The most recent insider tranaction occured on May, 30th when insider Salvatore Privitera bought 5,000 shares worth more than $111,250.00. Insiders at AtriCure own 3.2% of the company. Learn More about insider trades at AtriCure.

Information on this page was last updated on 5/30/2024.

Tonya Austin Insider Trading History at AtriCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/13/2022Sell3,203$42.69$136,736.0717,621View SEC Filing Icon  
4/8/2022Sell282$61.59$17,368.3820,824View SEC Filing Icon  
3/4/2022Sell1,409$67.66$95,332.94View SEC Filing Icon  
3/2/2022Sell1,626$69.31$112,698.06View SEC Filing Icon  
2/11/2022Sell2,490$67.97$169,245.30View SEC Filing Icon  
1/14/2022Sell2,719$66.11$179,753.09View SEC Filing Icon  
12/10/2021Sell1,528$70.88$108,304.64View SEC Filing Icon  
11/12/2021Sell2,732$78.55$214,598.60View SEC Filing Icon  
10/8/2021Sell665$71.80$47,747.00View SEC Filing Icon  
9/10/2021Sell1,227$77.18$94,699.8630,333View SEC Filing Icon  
8/13/2021Sell3,232$73.10$236,259.2031,560View SEC Filing Icon  
7/16/2021Sell493$78.03$38,468.79View SEC Filing Icon  
6/18/2021Sell2,620$76.36$200,063.2035,092View SEC Filing Icon  
See Full Table

Tonya Austin Buying and Selling Activity at AtriCure

This chart shows Tonya Austin's buying and selling at AtriCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AtriCure Company Overview

AtriCure logo
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Read More

Today's Range

Now: $21.20
Low: $18.94
High: $23.26

50 Day Range

MA: $22.58
Low: $19.86
High: $25.90

2 Week Range

Now: $21.20
Low: $18.94
High: $59.61


3,498,011 shs

Average Volume

538,934 shs

Market Capitalization

$1.01 billion

P/E Ratio


Dividend Yield